Karuna Therapeutics cut by analysts following news of Bristol-Myers Squibb acquisition
Tweet Send to a Friend
Karuna Therapeutics Inc. (NASDAQ: KRTX) was downgraded by analysts at Leerink Partners, H.C. Wainwright and Maxim Group on Tuesday following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


